Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) - Total Liabilities
Based on the latest financial reports, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) has total liabilities worth ₩79.37 Billion KRW (≈ $53.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Daishin Balance No.6 Special Purpose Acq generate cash to assess how effectively this company generates cash.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Total Liabilities Trend (2020–2024)
This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 307750 financial resilience to evaluate the company's liquid asset resilience ratio.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UBM Development AG
VI:UBS
|
Austria | €815.52 Million |
|
Prosafe SE
OL:PRS
|
Norway | Nkr351.70 Million |
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
Australia | AU$78.97 Million |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
USA | $27.68 Million |
|
Peninsula Energy Ltd
AU:PEN
|
Australia | AU$44.01 Million |
|
Bank Mnc Internasional Tbk
JK:BABP
|
Indonesia | Rp17.35 Trillion |
|
Fortinova Fastigheter AB Series B
ST:FNOVA-B
|
Sweden | Skr3.12 Billion |
|
Masterflex SE
F:MZX
|
Germany | €30.41 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Daishin Balance No.6 Special Purpose Acq worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)
The table below shows the annual total liabilities of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩114.85 Billion ≈ $77.83 Million |
-10.02% |
| 2023-12-31 | ₩127.65 Billion ≈ $86.50 Million |
+23.00% |
| 2022-12-31 | ₩103.77 Billion ≈ $70.33 Million |
+335.32% |
| 2021-12-31 | ₩23.84 Billion ≈ $16.15 Million |
-6.78% |
| 2020-12-31 | ₩25.57 Billion ≈ $17.33 Million |
-- |
About Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more